

Steps before prequalification

I BACKGROUND INFORMATION ON THE PROCEDURE

1. Submission of the dossier

The company Regeneron Pharmaceuticals, Inc. submitted in 2023 an application for INMAZEB 100 mg/mL solution for infusion in a vial, to be assessed with the aim of including INMAZEB in the list of prequalified medicinal products for the treatment of infection caused by *Zaire ebolavirus*.

INMAZEB was assessed according to the “WHO Procedure for Prequalification of BTPs or their corresponding SBPs”¹ and relevant applicable guidelines by the team of WHO assessors. The assessors are senior experts, mainly from national authorities, invited by WHO to participate in the prequalification assessment process.

The prequalification of this product by the WHO Prequalification of Medicines Programme is based on the approval by a stringent regulatory authority (SRA), namely the “U.S. FDA” (<https://www.fda.gov>) in line with the applicable guidelines².

Hence, no assessment of the data underlying this approval has been undertaken within the WHO Prequalification Team: Medicines (PQTm). However, according to the above-mentioned guideline WHO verified that the product, and in particular composition/formulation, strength, manufacturing, specifications, packaging, product information will, at the time of submission and after prequalification, in all respects, be the same as the product registered with the reference SRA (“verification”). Furthermore, WHO requested additional data for the safe use of the product in regions relevant for prequalified products and this information is included in the WHOPAR (part 6b). In order to safeguard product quality throughout its entire intended shelf-life, WHO assessed the evidence to verify the adherence to the principles outlined in the most recent version of the WHO guidelines on the international packaging and shipping of vaccines, also partially applicable to other biotherapeutic products³, to demonstrate suitability of the packaging to regions outside of climatic zone II. The WHO assessment included the packaging procedures for international shipments and the validation protocols and reports of the shipping boxes used for supply of the prequalified product.

Based on the data submitted the team of assessors advised that INMAZEB be included in the list of prequalified medicinal products. INMAZEB was listed on 16 Nov 2023.

Licensing status:

Inmazeb has been licensed / registered in U.S.A.

2. Steps taken in the evaluation of the product

Aug-2023	The applicant submitted the dossier
Sep-2023	The assessment team reviewed the submitted data and accepted the dossier for assessment

¹ https://extranet.who.int/prequal/sites/default/files/document_files/01_Prequalification_procedure_General.pdf

²

https://extranet.who.int/prequal/sites/default/files/document_files/03_Prequalification_general_AbridgedPathway.pdf

³ https://apps.who.int/iris/bitstream/handle/10665/69368/WHO_IVB_05.23_eng.pdf?sequence=1

Sep 2023	The assessment team reviewed the submitted document and further data was requested on verification, quality and pharmacovigilance.
Oct 2023	The applicant's response letter was received.
Nov 2023	Data on verification, quality and pharmacovigilance were found to be in compliance with WHO requirements
Nov 2023	INMAZEB was included in the list of prequalified medicinal products.

II GENERAL CONDITIONS FOR THE PREQUALIFICATION

1. Manufacturer, Commitments and Inspection status

Name and address of the manufacturers of the biological active substance

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, NY 10591-6707

U.S.A.

Name and address of the manufacturers responsible for batch release

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, NY 10591-6707

U.S.A.

Commitments for Prequalification

The Applicant committed to submit to WHO following each marketing authorization, a brief discussion on how the Applicant has addressed, after product prequalification, any potential differences in healthcare settings, compared to SRAs, that have required a revision of the adequacy of the safety concerns, pharmacovigilance activities, risk minimisation measures and/or traceability of the product.

Inspection status

The sites are inspected by a stringent regulatory authority.